440 related articles for article (PubMed ID: 28758379)
21. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
[TBL] [Abstract][Full Text] [Related]
22. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.
Santoro A; Angelico G; Piermattei A; Inzani F; Valente M; Arciuolo D; Spadola S; Mulè A; Zorzato P; Fagotti A; Scambia G; Zannoni GF
Front Oncol; 2019; 9():778. PubMed ID: 31482065
[No Abstract] [Full Text] [Related]
23. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
25. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma.
Said I; Böhm S; Beasley J; Ellery P; Faruqi AZ; Ganesan R; Hirschowitz L; Jeetle S; Leen SL; McCluggage WG; McDermott J; Merard R; Millner TO; Trevisan G; Vella J; Gilks CB; Singh N
Int J Gynecol Pathol; 2017 Mar; 36(2):172-179. PubMed ID: 27362902
[TBL] [Abstract][Full Text] [Related]
26. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
27. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Chen X
Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
[TBL] [Abstract][Full Text] [Related]
28. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
30. Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
Akladios C; Baldauf JJ; Marchal F; Hummel M; Rebstock LE; Kurtz JE; Petit T; Afors K; Mathelin C; Lecointre L; Schrot-Sanyan S
Oncology; 2016; 91(6):331-340. PubMed ID: 27784027
[TBL] [Abstract][Full Text] [Related]
31. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas.
Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
Michaan N; Chong WY; Han NY; Lim MC; Park SY
Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
[TBL] [Abstract][Full Text] [Related]
33. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
34. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
35. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
36. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
[TBL] [Abstract][Full Text] [Related]
37. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
[TBL] [Abstract][Full Text] [Related]
38. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
39. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
40. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
Ramspott JP; Baert T; MacKintosh ML; Traut A; Ataseven B; Bommert M; Heitz F; Plett H; Schneider S; Waltering KU; Heikaus S; Harter P; du Bois A
Arch Gynecol Obstet; 2021 Oct; 304(4):1021-1032. PubMed ID: 33661392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
